Alterity Therapeutics Ltd ADR (ATHE)

$5.38 -0.20 (-3.58%)
Market Cap 48.68M
Revenue (ttm) 0.00
Net Income (ttm) -7.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,400
Avg Vol 57,330
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 72%
Beta 0.25
Analysts Strong Sell
Price Target $11.00

Company Profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Address:
500 Collins Street, Level 15, Melbourne, Australia
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jul. 9 at 7:02 PM
$ATHE whats waiting for shorts around the corner....
0 · Reply
stckmuncher
stckmuncher Jul. 8 at 10:46 PM
$ATHE THE BOYZ AND I LOADED UP TODAY…5Kish!!!
0 · Reply
ShowM3Th3Mon3y69
ShowM3Th3Mon3y69 Jul. 8 at 9:31 PM
$ATHE Surrounded by farms here in Indiana I am very familiar with the phrase “knee high by Fourth of July” in regards to growing corn. I know we are all a little disappointed we didn’t hear partnership news by America’s birthday, but the corn will be much sweeter when it’s full grown.
0 · Reply
GA09
GA09 Jul. 8 at 3:01 PM
$ATHE Continues to trade (and close) above $5 (although without the much needed volume). Market will send a signal (via huge volume in multiple days) IF/WHEN they got close to a strategic relationship announcement (partnership or acquisition). Markets have a way of sending signals (first) before the news.
0 · Reply
stckmuncher
stckmuncher Jul. 7 at 11:27 PM
$ATHE GET YOUR DICK AND BALLZ READY!
0 · Reply
Nuevoempresario
Nuevoempresario Jul. 7 at 8:42 PM
$ATHE why is it almost down 10%? 🥲
1 · Reply
motherlandreturns
motherlandreturns Jul. 7 at 5:56 PM
$ATHE Hold the $5 dollar mark
1 · Reply
stckmuncher
stckmuncher Jul. 7 at 11:41 AM
$ATHE 👀👀👀
0 · Reply
focafoca99
focafoca99 Jul. 7 at 11:16 AM
$ATHE confirmed FDA alignment on Phase 3 trial for ATH434 in MSA.
1 · Reply
Sha_B_Ral
Sha_B_Ral Jul. 7 at 9:47 AM
$ATHE Alterity Therapeutics, NASDAQ: ATHE Analyst consensus: Strong Buy Analysts covering the stock: 3 Average price target: Approximately US$12.67 Based on the current share price, this represents a potential upside of approximately 130% (about 115% to 136%, depending on the data provider).
0 · Reply
Latest News on ATHE
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434

2026-07-07T11:35:24.000Z - 2 days ago

Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Jul 7, 2026, 7:05 AM EDT - 2 days ago

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

ATHE

Alterity Therapeutics initiated with a Buy at JonesResearch

2026-06-29T20:30:18.000Z - 10 days ago

Alterity Therapeutics initiated with a Buy at JonesResearch

Alterity Therapeutics assumed with a Buy at Ladenburg

2026-06-16T11:57:21.000Z - 23 days ago

Alterity Therapeutics assumed with a Buy at Ladenburg

Alterity Therapeutics Slides: Corporate presentation

Jun 15, 2026, 6:00 PM EDT - 24 days ago

Alterity Therapeutics Slides: Corporate presentation

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

2026-06-09T11:21:44.000Z - 4 weeks ago

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Jun 9, 2026, 7:05 AM EDT - 4 weeks ago

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

ATHE

Alterity Therapeutics management to meet with BTIG

2026-06-03T17:30:12.000Z - 5 weeks ago

Alterity Therapeutics management to meet with BTIG

ATHE

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

May 19, 2026, 7:25 AM EDT - 7 weeks ago

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

ATHE

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

2026-05-11T12:01:08.000Z - 2 months ago

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

ATHE

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

May 11, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

ATHE

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

May 7, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

ATHE

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Apr 30, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

ATHE

Alterity Therapeutics Earnings release: Q3 2026

Apr 29, 2026, 6:00 PM EDT - 2 months ago

Alterity Therapeutics Earnings release: Q3 2026

Alterity Therapeutics Transcript: KOL event

Apr 28, 2026, 1:00 PM EDT - 2 months ago

Alterity Therapeutics Transcript: KOL event

Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting

2026-04-27T11:42:00.000Z - 2 months ago

Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting

ATHE

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Apr 27, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

ATHE

Alterity Therapeutics presents new data analyses from ATH434 trial

2026-04-22T11:44:01.000Z - 2 months ago

Alterity Therapeutics presents new data analyses from ATH434 trial

ATHE

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Apr 22, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

ATHE

Alterity Therapeutics appoints Cunningham to Board of Directors

2026-04-17T11:39:13.000Z - 2 months ago

Alterity Therapeutics appoints Cunningham to Board of Directors

ATHE

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

Apr 17, 2026, 7:25 AM EDT - 2 months ago

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

ATHE

Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434

2026-03-30T11:35:46.000Z - 3 months ago

Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434

ATHE

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Mar 30, 2026, 7:25 AM EDT - 3 months ago

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

ATHE

Alterity Therapeutics Transcript: NWR Virtual Healthcare Conference

Mar 24, 2026, 10:00 PM EDT - 3 months ago

Alterity Therapeutics Transcript: NWR Virtual Healthcare Conference

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Mar 9, 2026, 7:25 AM EDT - 4 months ago

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

ATHE

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

2026-03-04T12:31:53.000Z - 4 months ago

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

ATHE

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Mar 2, 2026, 7:25 AM EST - 4 months ago

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

ATHE

Alterity Therapeutics Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 4 months ago

Alterity Therapeutics Quarterly report: H1 2026

Alterity Therapeutics provides corporate update

2026-01-30T12:38:43.000Z - 5 months ago

Alterity Therapeutics provides corporate update

ATHE

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Jan 30, 2026, 7:25 AM EST - 5 months ago

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

ATHE

Alterity Therapeutics highlights key 2026 objectives

2026-01-21T12:36:56.000Z - 6 months ago

Alterity Therapeutics highlights key 2026 objectives

ATHE

Alterity Therapeutics initiated with a Speculative Buy at Canaccord

2025-12-17T12:20:29.000Z - 7 months ago

Alterity Therapeutics initiated with a Speculative Buy at Canaccord

ATHE

Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler

2025-11-20T19:05:26.000Z - 8 months ago

Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler

ATHE

Alterity Therapeutics Transcript: Bell Potter Healthcare Conference 2025

Nov 18, 2025, 9:30 PM EST - 8 months ago

Alterity Therapeutics Transcript: Bell Potter Healthcare Conference 2025

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Nov 12, 2025, 7:25 AM EST - 8 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

ATHE

Alterity Therapeutics presents analyses related to OH from ATH434-201 trial

2025-11-10T13:02:08.000Z - 8 months ago

Alterity Therapeutics presents analyses related to OH from ATH434-201 trial

ATHE

Alterity Therapeutics reports cash balance of A$54.46M as of September 30

2025-10-31T11:30:23.000Z - 8 months ago

Alterity Therapeutics reports cash balance of A$54.46M as of September 30

ATHE

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 31, 2025, 7:25 AM EDT - 8 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Earnings release: Q1 2026

Oct 31, 2025, 7:00 AM EDT - 8 months ago

Alterity Therapeutics Earnings release: Q1 2026

Alterity Therapeutics presents data from ATH434 Phase 2 trial

2025-10-09T11:30:21.000Z - 9 months ago

Alterity Therapeutics presents data from ATH434 Phase 2 trial

ATHE

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 9, 2025, 7:25 AM EDT - 9 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

ATHE

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 10 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

ATHE

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 8, 2025, 7:35 AM EDT - 10 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

ATHE

Alterity Therapeutics Transcript: Biotech Showcase

Sep 2, 2025, 10:30 PM EDT - 11 months ago

Alterity Therapeutics Transcript: Biotech Showcase

Alterity Therapeutics to Present at the Biotech Showcase

Sep 2, 2025, 7:25 AM EDT - 11 months ago

Alterity Therapeutics to Present at the Biotech Showcase

ATHE

Alterity Therapeutics Annual report: H2 2025

Aug 29, 2025, 3:30 AM EDT - 11 months ago

Alterity Therapeutics Annual report: H2 2025

Alterity Therapeutics Slides: Corporate Presentation

Jul 30, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Slides: Corporate Presentation

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 30, 2025, 7:25 AM EDT - 1 year ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Earnings release: Q4 2025

Jul 29, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q4 2025

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 28, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

ATHE

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jul 24, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

ATHE

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Jun 23, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

ATHE

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

ATHE

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 1 year ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

ATHE

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

ATHE

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 1 year ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Earnings release: Q3 2025

Apr 29, 2025, 6:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q3 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 28, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

ATHE

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Apr 10, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

ATHE

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

ATHE

Alterity Therapeutics Quarterly report: H1 2025

Feb 27, 2025, 6:00 PM EST - 1 year ago

Alterity Therapeutics Quarterly report: H1 2025

Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

ATHE

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 30, 2025, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

ATHE

Alterity Therapeutics Transcript: Study Result

Jan 29, 2025, 8:01 PM EST - 1 year ago

Alterity Therapeutics Transcript: Study Result

Alterity Therapeutics Slides: Study Result

Jan 29, 2025, 8:01 PM EST - 1 year ago

Alterity Therapeutics Slides: Study Result

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Jan 9, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

ATHE

Alterity Therapeutics Slides: Corporate Presentation

Jan 4, 2025, 8:00 PM EST - 1 year ago

Alterity Therapeutics Slides: Corporate Presentation

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

ATHE

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

ATHE

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Earnings release: Q1 2025

Oct 30, 2024, 9:00 PM EDT - 1 year ago

Alterity Therapeutics Earnings release: Q1 2025

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics Annual report: H2 2024

Sep 26, 2024, 3:30 AM EDT - 1 year ago

Alterity Therapeutics Annual report: H2 2024

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 2 years ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Earnings release: Q4 2024

Jul 30, 2024, 8:00 PM EDT - 2 years ago

Alterity Therapeutics Earnings release: Q4 2024

Alterity Therapeutics Transcript: Study Update

Jul 24, 2024, 6:30 PM EDT - 2 years ago

Alterity Therapeutics Transcript: Study Update

Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 2 years ago

Alterity Therapeutics to Present at MST Financial Webinar

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:35 AM EDT - 2 years ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Jun 12, 2024, 7:22 PM EDT - 2 years ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 2 years ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

AshleySchaeffer_BMW
AshleySchaeffer_BMW Jul. 9 at 7:02 PM
$ATHE whats waiting for shorts around the corner....
0 · Reply
stckmuncher
stckmuncher Jul. 8 at 10:46 PM
$ATHE THE BOYZ AND I LOADED UP TODAY…5Kish!!!
0 · Reply
ShowM3Th3Mon3y69
ShowM3Th3Mon3y69 Jul. 8 at 9:31 PM
$ATHE Surrounded by farms here in Indiana I am very familiar with the phrase “knee high by Fourth of July” in regards to growing corn. I know we are all a little disappointed we didn’t hear partnership news by America’s birthday, but the corn will be much sweeter when it’s full grown.
0 · Reply
GA09
GA09 Jul. 8 at 3:01 PM
$ATHE Continues to trade (and close) above $5 (although without the much needed volume). Market will send a signal (via huge volume in multiple days) IF/WHEN they got close to a strategic relationship announcement (partnership or acquisition). Markets have a way of sending signals (first) before the news.
0 · Reply
stckmuncher
stckmuncher Jul. 7 at 11:27 PM
$ATHE GET YOUR DICK AND BALLZ READY!
0 · Reply
Nuevoempresario
Nuevoempresario Jul. 7 at 8:42 PM
$ATHE why is it almost down 10%? 🥲
1 · Reply
motherlandreturns
motherlandreturns Jul. 7 at 5:56 PM
$ATHE Hold the $5 dollar mark
1 · Reply
stckmuncher
stckmuncher Jul. 7 at 11:41 AM
$ATHE 👀👀👀
0 · Reply
focafoca99
focafoca99 Jul. 7 at 11:16 AM
$ATHE confirmed FDA alignment on Phase 3 trial for ATH434 in MSA.
1 · Reply
Sha_B_Ral
Sha_B_Ral Jul. 7 at 9:47 AM
$ATHE Alterity Therapeutics, NASDAQ: ATHE Analyst consensus: Strong Buy Analysts covering the stock: 3 Average price target: Approximately US$12.67 Based on the current share price, this represents a potential upside of approximately 130% (about 115% to 136%, depending on the data provider).
0 · Reply
5xMoneyTree
5xMoneyTree Jul. 7 at 1:23 AM
$ATHE I see 30 dollars easy
0 · Reply
ATHEMillie
ATHEMillie Jul. 7 at 12:22 AM
$ATHE don’t call me Nostradamus but call me Victor the Predictor 😋 Account finally unblocked :)
0 · Reply
stckmuncher
stckmuncher Jul. 7 at 12:00 AM
$ATHE ORDERS FILLING AT $6.50 DURING AH!!!!!!
1 · Reply
stckmuncher
stckmuncher Jul. 6 at 11:59 PM
$ATHE 👀👀👀
0 · Reply
stckmuncher
stckmuncher Jul. 6 at 11:40 PM
$ATHE Where is everyone?
1 · Reply
tommy_john
tommy_john Jul. 6 at 7:27 PM
$ATHE this now needs a lot of volume to come in
0 · Reply
ShowM3Th3Mon3y69
ShowM3Th3Mon3y69 Jul. 6 at 2:28 PM
$ATHE
1 · Reply
stckmuncher
stckmuncher Jul. 6 at 1:48 PM
$ATHE 🚀🚀🚀
0 · Reply
stckmuncher
stckmuncher Jul. 6 at 1:48 PM
$ATHE CAUGHT THE ATTENTION OF HUGE MUTUAL FUNDS!!!!!
0 · Reply
stckmuncher
stckmuncher Jul. 6 at 12:28 AM
$ATHE Huge potential!
0 · Reply
stckmuncher
stckmuncher Jul. 5 at 7:20 PM
$ATHE $43.68 by year end buy out or not…🚀🚀🚀CLOCK IT BITCH
1 · Reply
stckmuncher
stckmuncher Jul. 5 at 7:20 PM
$ATHE 🚀🚀🚀💥💥💥$25+
0 · Reply